anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Preschoolers experience physical symptoms, like abdominal pain or minor injuries, almost every day. These experiences may shape how they deal with health issues later in life. To gain insight into these early life experiences, information from multiple perspectives is useful. This qualitative study aimed to explore important themes in preschoolers' experience of physical symptoms, using adult professionals from various backgrounds as informants.
METHODS: 20 semi-structured interviews were performed with professionals from different fields in healthcare and education, to learn about their ideas and observations on preschoolers' experiences with physical symptoms. The interviews were verbatim transcribed and coded in Atlas.ti by two independent coders, after which thematic content analysis was applied to define themes.
RESULTS: Three themes emerged from the interviews: unawareness, seeking attention, and parental influence. Unawareness refers to the professionals' idea that preschoolers have limited cognitions about causes and consequences of physical symptoms. Seeking attention was described as important for preschoolers with symptoms, both as comfort and in a social context. Professionals described diminished attention-seeking behavior in preschoolers with more severe symptoms. Parental influence was seen as highly relevant in preschoolers' experiences with physical symptoms, with both supportive and disruptive aspects. Healthcare professionals differed from educational professionals in their observations and ideas, especially about underlying mechanisms influencing symptoms.
CONCLUSIONS: Professionals report attention-seeking and parental influence as important factors in preschoolers with physical symptoms, and they report limited cognitions about causality. Professionals in healthcare and education show different perceptions, suggesting the importance of incorporating both views into research.
INTRODUCTION: Human papillomavirus (HPV) infection is the most prevalent sexually transmitted infection worldwide. HPV vaccination is an important tool to prevent and control HPV infection and its complications. Despite carrying the severe burden of disease, HPV vaccine coverage in Africa remains low. The aim of the current review is to evaluate the factors associated with HPV vaccination acceptance among adolescent men and women, young men and women, parents/caregivers, men who have sex with men, healthcare workers and programme managers in Africa.
METHODS AND ANALYSIS: We will include peer-reviewed quantitative studies. We will search PubMed, Scopus, PsycInfo, Web of Science and Cochrane Central Register of Controlled Trials, with no language restriction, to identify eligible studies. Two review authors will independently screen the titles and abstracts of the search output in Covidence to select potentially eligible studies. The same two reviewers will independently screen the full-text of all identified potentially eligible articles to identify studies meeting inclusion criteria. Two review authors will independently extract data from eligible studies using a predefined data extraction form. Two review authors will independently assess the risk of bias in each included study, using the Effective Public Health Practice Project 'Quality Assessment Tool for Quantitative Studies'. We will assess the quality of evidence using the method for Grading of Recommendations Assessment, Development and Evaluation.
ETHICS AND DISSEMINATION: Ethical approval is not required for this study because we will use already published data. The results of this review will be disseminated through peer-reviewed publication and conference presentation.
PROSPERO REGISTRATION NUMBER: CRD42023475810.
Temporal phases of wound healing and their corresponding healing factors are essential in wound regeneration. Mesenchymal stem cells (MSCs) accelerate wound healing via their paracrine secretions by enhancing cell migration, angiogenesis, and reducing inflammation. This study evaluated the local therapeutic effect of human umbilical cord MSCs (hUCMSCs) in the healing of cold-induced burn wounds. An in vitro wound (scratch) was developed in rat skin fibroblasts. The culture was maintained in the conditioned medium (CM) which was prepared by inducing an artificial wound in hUCMSCs in a separate experiment. Treated fibroblasts were analyzed for the gene expression profile of healing mediators involved in wound closure. Findings revealed enhanced cell migration and increased levels of healing mediators in the treated fibroblasts relative to the untreated group. Cold-induced burn wounds were developed in Wistar rats, followed by a single injection of hUCMSCs. Wound healing pattern was examined based on the healing phases: hemostasis/inflammation (Days 1, 3), cell proliferation (Day 7), and remodeling (Day 14). Findings exhibited enhanced wound closure in the treated wound. Gene expression, histological, and immunohistochemical analyses further confirmed enhanced wound regeneration after hUCMSC transplantation. Temporal gene expression profile revealed that the level of corresponding cytokines was substantially increased in the treated wound as compared with the control, indicating improvement in the processes of angiogenesis and remodeling, and a substantial reduction in inflammation. Histology revealed significant collagen formation along with regenerated skin layers and appendages, whereas immunohistochemistry exhibited increased neovascularization during remodeling. Leukocyte infiltration was also suppressed in the treated group. Overall findings demonstrate that a single dose of hUCMSCs enhances wound healing in vivo, and their secreted growth factors accelerate cell migration in vitro.
OBJECTIVES: The management of type 1B endoleaks following endovascular aortic aneurysm repair (EVAR) can be challenging. The Heli-FX Endoanchor system effectively treats proximal type 1A endoleaks but has not been used for type 1B common iliac artery endoleaks. This study demonstrates that it is both safe and effective in being used in the common iliac artery (CIA) limb of an EVAR.
METHODS: A retrospective review of patients identified through coding and medical records was performed to extract information on demographics, aneurysmal features, operative features, and postoperative outcomes. This was then collated and analysed thoroughly and compared to existing research.
RESULTS: Four patients with six type 1B CIA endoleaks were treated with Heli-FX Endoanchors in the CIA limbs of EVAR grafts. There was 100% technical success rate with complete exclusion of the endoleaks at 6 months. With mean follow up of 714 days, there were no Endoanchor-specific complications. One patient required explantation of the aortic endograft due to contralateral limb fracture, where it was found that an Endoanchor had penetrated the common iliac vein, requiring primary closure.
CONCLUSIONS: Heli-FX Endoanchors were effective within this cohort of patients, though key risks were identified. Adjacent anatomy to the CIA must be considered, which also have nearly half the arterial thickness compared to the aorta. Pre-operative planning is essential given the theoretical risk of placing Endoanchors.
Rocabado´s 6 x 6 exercises program utilizes six exercises six times by day. The patient is in supine position with a loop of 6 cm in the cervical area, and the therapist sits at the head of the bed.
BACKGROUND: Acute pancreatitis is observed more frequently in the pediatric age. Currently, there are recommendation guidelines for its proper diagnosis and treatment. The objective of this study was to evaluate the level of knowledge of the international recommendations on acute pancreatitis in pediatrics of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition in a group of pediatricians.
METHODS: Observational, multicenter study, through a survey applied to pediatricians and pediatric residents.
RESULTS: 48.8% of physicians had prior knowledge of the guidelines for the treatment of acute pancreatitis in children. 72.4% knew the current criteria for the diagnosis of acute pancreatitis. There were no differences in the majority of responses between pediatricians and pediatric residents.
CONCLUSIONS: Although only half of the respondents followed the guidelines for diagnosis and treatment of acute pancreatitis, about three-quarters adequately use the criteria for diagnosis. There is adequate knowledge about the prescription of antibiotics and pancreatitis follow-up. There is lack of knowledge on the recommendation of monitoring vital signs and the precise time to perform cholecystectomy in the pancreatitis of biliary origin.
A parallel group randomized controlled clinical trial will be conducted during the months of November 2022 to December 2023. The proposed research will be a quantitative experimental design type controlled clinical trial following the SPIRIT guidelines for clinical trial protocols and CONSORT for the execution of clinical trials.

A total of 80 patients, where 40 will be assigned to (PNE) and 40 to conventional management. experimental group: based on education in neuroscience of pain for 9 sessions in a period of 10 weeks. Work will be done to prepare the content for an adapted and illustrated guide as a complementary material for patients. An expert judgment test will be carried out to validate the content of the material. Each patient must complete at least 8 sessions to comply with the protocol. These sessions will be personalized and will include the guide as complementary material for each session. This group remains with pharmacological treatment and the usual guidelines given by the doctor. Results will be assessed at baseline (t1) and at week 10 (t2). Written informed consent will be obtained from all participants prior to their participation.
NEW MATERIAL:A glycoprotein complex obtained from Volvariella volvacea and having the following characteristics. Apperance, white amorphous powder; solubility, soluble in water and dimethyl sulfoxide, insoluble in methanol, benzene, etc.; molecular weight, 10,000-50,000 (by gel-filtration); composition, the weight ratio of sugar to protein is 20/80-80/20, the sugar is composed solely of glucose; protein is composed of aspartic acid, glutamic acid, alanine, leucine, etc.; elemental analysis (%), C 40-53, H 5.8-6.8, N 28-12. USE:An antitumor agent exhibiting extremely strong suppressing effect especially against sarcoma 180 solid cancer, and having extremely low toxicity. PREPARATION:Volvariella volvaces is extracted with cold alkali, the extracted fraction is eluted successively with a phosphate buffer solution, an NaCl solution and an NaOH solution using an anion-exchange column, the second fraction is collected, and the fraction having a molecular weight of 10,000-50,000 is separated by using a gel-filtration agent to obtain the objective glycoprotein complex.
A total of 6 times hAESCs transplants will be performed. 50 million (in 2ml) hAESCs will be transplanted into the ventricle of participants through the Ommaya sac (set as day 0 at the beginning of the trial). Subsequently, hAESCs ventricle transplants will be performed at 1 month ±5 days, 2 months ±5 days, 3 months ±5 days, 6 months ±5 days, and 9 months ±5 days after the first cell transplantation, with a volume of 50 million cells (in 2 ml) each time.
The invention relates to a method of producing connective tissue growth factor (CTGF). A method of the invention can be performed, for example, by transforming a host cell with a polynucleotide encoding a CTGF polypeptide having an amino acid sequence of SEQ ID NO: 2 or an active fragment thereof; and growing the host cells under conditions suitable for expressing the polynucleotide in the host cell. In an embodiment, the method further involves isolating the CTGF polypeptide or the active fragment. The invention also relates to a method for producing a vector containing a polynucleotide encoding a CTGF polypeptide or an active fragment thereof by inserting a polynucleotide encoding a CTGF polypeptide having an amino acid sequence of SEQ ID NO: 2 or a variant thereof into the vector. The vector can be an expression vector, for example, a plasmid expression vector or a viral expression vector. In an embodiment, the polynucleotide has a nucleotide sequence of SEQ ID NO: 1 or a variant thereof.
PURPOSE: KRASG12D mutation (mut) occurs in about 10%-12% of metastatic colorectal cancer (mCRC). Recently, novel KRASG12D inhibitors have been developed and are currently under investigation in phase I/II clinical trials in solid tumors including mCRC. We aimed at performing a comprehensive characterization of clinical, molecular, immunologic, and prognostic features of KRASG12D-mutated mCRC to inform the design and the interpretation of future trials.
METHODS: We performed a pooled analysis of phase III TRIBE and TRIBE2 studies comparing 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/bevacizumab (bev) to doublets (5-fluorouracil, leucovorin, and oxaliplatin or 5-fluorouracil, leucovorin, and irinotecan)/bev.
RESULTS: One hundred and thirty-six (16%) of 854 patients with available KRASG12D mutational status were KRASG12D mutated. KRASG12D-mutated patients had more frequently right-sided primary tumor and were less likely to present liver-only metastases with respect to other RAS mutated and all-wild-type (wt) patients. Compared with the BRAFV600E-mutated group, KRASG12D-mutated patients had more frequently left-sided primary tumor, resected primary tumor at the time of diagnosis, and Eastern Cooperative Oncology Group performance status 0. KRASG12D-mutated patients had better prognosis than BRAFV600E-mutated and worse prognosis than all wt patients. No prognostic difference was evident between KRASG12D mut and other RAS mut patients overall or according to other specific KRAS or NRAS hotspot mutations. No interaction effect was observed between KRASG12D mut and the benefit provided by FOLFOXIRI/bev compared with doublets/bev. PIK3CA mut were reported more frequently among KRASG12D-mutated tumors compared with both other RAS mut and all wt.
CONCLUSION: A detail estimation of KRASG12D mut mCRC patients' characteristics and expected outcomes may be useful when planning future studies in this subgroup. The high prevalence of PI3K/PTEN/Akt pathway activating alterations may affect the efficacy of targeted strategies.
PURPOSE:To obtain a health food reduced in the excreted amount of Ca awing to the chitosan, replenishing Ca in vivo without inhibiting the hypotensive activity of the chitosan, by incorporating chitosan with ground shell as Ca. CONSTITUTION:This health food is obtained by incorporating 100 pts.wt. of chitosan with pref. 75 pts.wt,, in terms of calcium, of ground shell as calcium. The shell to be used is derived from that of e.g. oyster, scallop, crab, mollusk, arthropod.
A prohibited object detection system detects prohibited objects in a patient room. An image of an object detected in a room of a patient is initially collected. The system identifies reference points on the object, for example, points along the contours of the object. The system may compare the reference points to reference points of images associated with prohibited objects. The system then determines, based on the comparison, if the object is a prohibited object. One or more designated recipients may be alerted if the object is a prohibited object. The system may also register the object in a database of prohibited objects.
Patients with EHEC associated bloody diarrhoea (n=21)receiving SOC-treatment, consisting of i.v. fluids (2-3 liter/day), analgetics ( paracetamol and metamizol) or metoclopramid and orally administered polyethylene glycol-solution daily during the clinical course.
Participants aged 3 to 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
PROBLEM TO BE SOLVED: To prepare an adhesive for dental resin material, having a moderate viscosity, excellent in operating efficiency or aesthetic properties without causing a residual color, having a sufficient adhesive strength independently of a combination of an acrylic resin material with an acrylic resin-based composite material and safe even when used in oral cavity. SOLUTION: This adhesive for dental resin material is prepared by adding 0.04-0.12 pt.wt. photopolymerization initiator to 100 pts.wt. mixture comprising 90-60 pts.wt. monomer mixture composed of tetrahydrofurfuryl methacrylate and 2-hydroxyethyl methacrylate at (1:1) to (1:3) weight ratio and 10-40 pts.wt. one or more methacrylates having at least one unsaturated double bond in one molecule.
An antidiarrheal composition comprises a copolymer of maleic anhydride, a vinyl or vinylidene compound as cross-linking agent and an olefine of formula R-CH = CH2, where R is H, C1- 5 alkyl or C1- 3 alkoxy, the copolymer having a viscosity of 10,000-100,000 cp. in 1% aq. solution at 25 DEG  C. and pH 9.  The cross-linking agent may be styrene, methyl methacrylate, vinyl acetate or vinyl crotonate.  The olefine may be ethylene, propylene, (di)-iso butylene, butene-1, or methyl or ethyl vinyl ethers.  The copolymer may be partially hydrolysed so as to convert 5-25% of the anhydride residues to carboxyl groups. The compositions may contain sodium cyclomate, citrate, chloride and glutamate, saccharin, vanillin, magnesium stearate and mannitol.  The copolymer may be prepared by reacting the monomers in an organic solvent, e.g. toluene, and in the presence of a catalyst, e.g. benzoyl, acetyl, butyryl, succinyl, lauroyl or cumyl peroxides.ALSO:An antidiarrheal composition comprise a copolymer of maleic anhydride, a vinyl or vinylidene compound as cross-linking agent and an olefine of formula R-CH=CH2 where R is H1 C1-5 alkyl or C1-3 alkoxy, the copolymer having a viscosity of 10,000-100,000 cp. in 1% ag. solution at 25 DEG C. and pH9.  The cross-linking agent may be styrene, methyl methacrylate vinyl acetate or vinyl crotonate. The olefine may be ethylene, propylene, (di)-isobutylene, butene-1, or methyl or ethyl vinyl ethers.  The copolymer may be partially hydrolysed so as to convert 5-25% of the anhydride residues to carboxyl groups.  The composition may be in dosage form, e.g. a tablet or capsule or an oral suspension in which the pharmaceutical carrier is a liquid e.g. an alcohol soluble modified triglyceride derived from coconuts.
In this Randomized control trial, N=180 participants would be enrolled for eligibility assessment from different shelter homes in the cities of Punjab after the eligibility assessment and screening 108 participants would be allocated to experimental and waitlist treatment conditions. Participants will be allocated through matchable group characteristics. Participant's age range would be between 18 to 45 years. Each of the group will be comprised of the same number of participants. Both groups will be pre-tested and results will be recorded. A cognitive behavior therapy-based treatment plan will be formulated to address Depression, Stigmatization, Excessive Worries, and Emotional Management among Women Facing Partner Violence. 8-10 CBT-based therapeutic sessions with 60 minutes will be conducted with the participant in a one-on-one setting.
Biomedical researchers tirelessly seek cutting-edge technologies to advance disease diagnosis, drug discovery, and therapeutic interventions, all aimed at enhancing human and animal well-being. Within this realm, proteomics stands out as a pivotal technology, focusing on extensive studies of protein composition, structure, function, and interactions. Proteomics, with its subdivisions of expression, structural, and functional proteomics, plays a crucial role in unraveling the complexities of biological systems. Various sophisticated techniques are employed in proteomics, including polyacrylamide gel electrophoresis, mass spectrometry analysis, NMR spectroscopy, protein microarray, X-ray crystallography, and Edman sequencing. These methods collectively contribute to the comprehensive understanding of proteins and their roles in health and disease. In the biomedical field, proteomics finds widespread application in cancer research and diagnosis, stem cell studies, and the diagnosis and research of both infectious and noninfectious diseases. In addition, it plays a pivotal role in drug discovery and the emerging frontier of personalized medicine. The versatility of proteomics allows researchers to delve into the intricacies of molecular mechanisms, paving the way for innovative therapeutic approaches. As infectious and noninfectious diseases continue to emerge and the field of biomedical research expands, the significance of proteomics becomes increasingly evident. Keeping abreast of the latest developments in proteomics applications becomes paramount for the development of therapeutics, translational research, and study of diverse diseases. This review aims to provide a comprehensive overview of proteomics, offering a concise outline of its current applications in the biomedical domain. By doing so, it seeks to contribute to the understanding and advancement of proteomics, emphasizing its pivotal role in shaping the future of biomedical research and therapeutic interventions.
Transdominant HIV tat substitution and truncated gene mutants of 72 amino acid residues or less are disclosed. The mutated genes encode mutant Tat proteins which are capable of inhibiting the expression of the HIV-1 virus in the presence of an equimolar concentration of the wild type Tat protein in vitro. Therapeutic agents which include fused protein forms of the mutant proteins are also disclosed, as well as methods of preparing and using the therapeutic agents in the treatment of HIV infection and HIV-related injections in an animal. Recombinant vectors which express the mutant HIV Tat proteins described are also disclosed, as well as cell lines which product high yields of the mutant HIV. Also provided are cell lines that express enhanced levels of TAR mutant viruses relative to other TAR mutant infected cell lines. Levels of production are enhanced by the use of cell lines that express a transactivator protein, such as adenovirus transactivator EIA and/or EIB protein. Methods of preparing these cell lines, as well as vaccines from virus produced by these cell lines, are also disclosed.
The present invention relates to compositions and methods for screening compounds that modulate meiotic progression. In particular, it relates to compositions comprising nucleotides from the mouse 5′ regulatory region, and transcriptionally active fragments thereof, that control the expression of a testis-enriched protein, SP-10. Specifically provided are expression vectors, host cells, and transgenic animals. The SP-10 promoter controls the expression of a heterologous gene, e.g., green fluorescent protein. The invention relates to methods for using the vectors, cells, and animals for screening candidate molecules for agonists and antagonists of sperm development and fertilization. Methods for using molecules and compounds identified by the screening assays for therapeutic treatments are provided.
Subjects will be men and women, 40 years of age or older, who enroll in Exact Sciences Protocol 2019-01 BLUE-C. Subjects will provide a blood sample at time of enrollment.